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Abstract: The main purpose of this study was to investigate the hepatotoxic potential and effects on
the gut microbiome of decaffeinated green tea extract (dGTE) in lean B6C3F1 mice. Gavaging dGTE
over a range of 1X–10X mouse equivalent doses (MED) for up to two weeks did not elicit significant
histomorphological, physiological, biochemical or molecular alterations in mouse livers. At the same
time, administration of dGTE at MED comparable to those consumed by humans resulted in significant
modulation of gut microflora, with increases in Akkermansia sp. being most pronounced. Results
of this study demonstrate that administration of relevant-to-human-consumption MED of dGTE to
non-fasting mice does not lead to hepatotoxicity. Furthermore, dGTE administered to lean mice,
caused changes in gut microflora comparable to those observed in obese mice. This study provides
further insight into the previously reported weight management properties of dGTE; however, future
studies are needed to fully evaluate and understand this effect.
Keywords: catechins; green tea extract; herbal dietary supplements; hepatotoxicity; microbiome
1. Introduction
The importance of dietary polyphenols for systemic health benefits is becoming increasingly
recognized. Green tea, a major source of catechin polyphenols, is the second most popular beverage
in the world and extracts of green tea are common ingredients in many dietary supplements. Major
green tea extract (GTE) catechins include epicatechin (EC), epicatechin gallate (ECG), epigallocatechin
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(EGC) and epigallocatechine gallate (EGCG), where the latter constitutes 50-80% of total catechins [1,2].
Catechins are reported to exert a number of positive effects on human health, including antioxidant,
antibacterial and anti-inflammatory activities as well as reduced risks for cancer and cardiovascular
disease [3–6]. Furthermore, the association of green tea or GTE consumption with weight loss and
weight management, has further attracted interest to studies on catechins [7,8]. While these claims
are based mostly upon the results of animal studies or equivocal clinical trial findings, the popularity
of GTE and GTE-containing herbal dietary supplements (HDS) continues to grow. At the same time,
GTE and its various catechin components (mainly–EGCG) are linked to a number of hepatotoxicity
cases [9–15]. This hepatotoxicity has been confirmed experimentally and was shown to be further
exacerbated by fasting conditions [16–19]. Therefore, the first aim of this study was to investigate
potential hepatotoxicity and associated mechanisms of decaffeinated GTE (dGTE) in non-fasting mice.
The potentially beneficial effects associated with GTE and their mechanisms remain poorly
understood. It has been demonstrated that short-term ingestion of GTE increases energy expenditure
and promotes weight loss among lean and overweight volunteers but the long-term effects of GTE on
energy expenditure were less conclusive [20–25]. Other hypotheses include GTE-mediated effects on
sympathetic nervous system activity and promotion of fat oxidation [8]. Furthermore, a number of
in vitro studies have indicated that EGCG inhibits adipocyte differentiation and proliferation while
inducing adipocyte apoptosis [26–28]. However, it must be recognized that most in vitro studies have
utilized EGCG concentrations (50–400 µM) much greater than that typically observed in humans (up to
1 µM) following GTE ingestion [29]. Furthermore, it is become increasingly recognized that intestinal
absorption of catechins is at best nominal with less than 30% of ingested green tea polyphenols reaching
the systemic circulation [30–34]. Poor absorption coupled with extensive first-pass metabolism likely
explains the poor tissue accumulation of catechins following oral ingestion [35,36]. Therefore, the
purported health benefits of GTE are not readily attributable to circulating levels of catechins.
Substantial levels of unabsorbed catechins, mainly EGCG, have been shown to reach the proximal
and distal colon [37,38]. To what extent gut microbial metabolism plays a role in mediating GTE’s health
benefits remains to be determined. However, accumulating evidence indicates that GTE can modulate
the gut microbiome in both experimental models and in humans [39–42]. Therefore, it has been
proposed that GTE’s health benefits may be linked to the effects catechins exert on particular bacterial
species in the gut. Recent studies report similar patterns in the effects GTE causes on the gut microbiome
in both experimental models and in human subjects. Those patterns are characterized by higher
Shannon and Simpson microbiome diversities, increases in abundance of Bacteroidetes concomitant with
deceases in Firmicutes at the phyla level and increases in Prevotellaceae and Bacteroidaceae paralleled by
decreases in Eubacteriaceae, Lachnospiraceae, Ruminococcaceae and Clostridiaceae at the family level [39–41].
These studies, however, were performed on obese individuals or obese/fed high-fat diet mice; however,
the effects of GTE on the gut microbiome associated with the lean phenotype remain unknown.
Therefore, the second aim of this study was to investigate the effects of dGTE on the gut microbiome as
a result of short-term ingestion in lean B6C3F1 mice.
2. Materials and Methods
2.1. Decaffeinated Green Tea Extract (dGTE)
The studied product was a standardized dGTE manufactured by Nature’s Way (Green Bay, WI,
USA; lot # 20055697, expiration 11/30/18). The gavage solution was prepared by extracting the contents
of 10 capsules with 10 mL of distilled water (pH = 5.3) in 20 mL round bottom, glass screw cap tubes
via rotation (12 revolutions per minute) for 24 h. Tubes were then centrifuged at 10,000 rpm for 1 h, the
supernatant was collected and two 1 mL aliquots were analyzed by the University of Mississippi’s
National Center for Natural Products Research for analysis (NCNPR).
dGTE was characterized for phytochemical content using validated analytical methods
incorporating ultra-high performance liquid chromatography (UPLC) coupled with photodiode
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array (PDA) and mass spectrometry (MS) detection previously developed for the quantitative analysis
of caffeine, theobromine and individual catechins (i.e., catechin, epicatechin, epicatechin gallate,
epigallocatechin gallate) in Camellia sinensis leaves and GTE-containing products. Quantitative analysis
was performed using a Waters Acquity UPLCTM H-class system (Waters Corp., Milford, MA, USA)
including a quaternary solvent manager, sample manager, column compartment and PDA (Waters
Acquity model code UPD) connected to a Waters Empower 2 data station. Separations were achieved
within 15 min using a Waters C18 column. The injection volume was 2 µL and the PDA wavelength
was 230 nm. The effluent from the LC column was directed into an electrospray ionization (ESI) probe.
Compounds were confirmed under both positive and negative ionization modes.
2.2. Animals
Male B6C3F1/J mice, 8 weeks of age, were purchased from Jackson Laboratories (Bar Harbor, ME)
and were housed at the UAMS Division of Laboratory Animal Medicine facility. B6C3F1/J mice are
characterized by an average sensitivity to hepatotoxicants and are widely used by both the U.S. Food
and Drug Administration (FDA) and industry to investigate the potential for xenobiotics to produce
hepatotoxicity. Male mice were used on account of previous reports indicating a higher sensitivity
to GTE-induced toxicity in male animals [17]. Animals were given one week to acclimate before the
initiation of studies. Animal experiments were conducted in two stages. In the first stage, mice were
gavaged with a single dose of either 1X, 3X or 10X mouse equivalent doses (MED) of dGTE with
the subsequent tissue harvest at 24 h. This stage was performed in order to address the potential
for acute toxicity of dGTE. During the second stage, mice were gavaged with dGTE for two weeks
(Mon-Fri). The duration of this stage was chosen to investigate dGTE’s sub-acute toxicity. To avoid
potential fasting-exacerbated toxicity, food and water were provided ad libitum. Animal body weights
were measured and recorded twice a week. All procedures were approved by the UAMS Institutional
Animal Care and Use Committee at UAMS (protocol number: AUP #3701).
2.3. Dosage Information/Dosage Regimen
Allometric scaling for mouse equivalent doses for dGTE was determined per the recommendation
of Wojcikowski and Gobe [43] which, in turn, is based upon the FDA Industry Guidance for Estimating
the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Volunteers [44].
According to the label, each capsule 250 mg of dGTE was standardized to 95% polyphenols
(75% catechins). Label recommended dose was “2 capsules daily, preferably with food.” The human
dose of catechins was calculated to be 375 mg catechins/70 kg = 5.36 mg/kg. MED of dGTE was
calculated as 5.36 mg/kg × 12.3 = 65.9 mg/kg, where 12.3 is the scaling factor commonly used for mice
weighing between 11–34 g. Concentration of total catechins per mL for the Nature’s Way extraction
solution as determined by NCNPR was 723.5 mg/mL. Therefore, for the 1X MED, the quantity of
catechins administered was 65.9 mg/kg × 0.0235 kg (average mouse weight in our study) = 1.5 mg total
catechins delivered in 300 µL of gavage solution. Consequently, 3X MED = 4.5 mg total catechins and
10X MED = 15 mg total catechins.
All extract supernatants were kept in the refrigerator and gavage doses were prepared fresh each
day. After 40 days, a reanalysis of the catechin content of the supernatants was performed and the
total catechin concentration was 92% of the original quantity.
2.4. Blood Sampling and Clinical Biochemistry
To measure the effects of dGTE on the panel of enzymes characteristic for liver injury, blood was
collected at the end of each experimental stage. Blood was collected under isoflurane anesthesia from
the retroorbital plexus. Tubes were kept on ice and centrifuged at 10,000 rpm for 20 min; serum samples
were then immediately aliquoted and delivered to Arkansas Livestock and Poultry Commission
Veterinary Diagnostic Laboratory (Little Rock, AR, USA) where the samples were processed same day.
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2.5. Histopathological Assessment
Livers were excised, and a 1 mm section was obtained from the left lateral lobe and another from
the right medial lobe. The sections were fixed in 4% formalin for 24 h, then briefly rinsed in PBS and
stored in 70% ethanol for 24 h. Livers were then processed at the UAMS Pathology Core Facility,
stained with hematoxylin eosin and shipped to the Heartland Veterinary Pathology Services, PLLC
(Edmond, OK) where they were assessed by a board-certified veterinary pathologist in a blind fashion.
For histologic evaluation purposes, each liver was represented by two sections obtained from
different lobes. Each section was initially evaluated at magnifications of 4 × 0 and 100X. The sections
were then evaluated at 200X and 400X to better determine if significant changes were present and to
check for the presence of mitotic figures and apoptotic bodies.
2.6. Glutathione Analysis
Glutathione was measured using a modified Tietze assay [45]. Briefly, liver tissue was homogenized
in 3% sulfosalicylic acid. One aliquot was diluted in N-ethylmaleimide (NEM) to mask reduced
glutathione (GSH) to facilitate measurement of oxidized glutathione (GSSG), while another was diluted
in 0.1 M HCl for measurement of total (GSH+GSSG) glutathione. After removal of NEM by solid
phase extraction with a C18 column, glutathione was measured in both aliquots using a colorimetric
glutathione reductase cycling detection method [45].
2.7. Gene Expression Array
Total RNA was extracted from flash frozen liver tissue using the RNeasy Mini Kit (Qiagen,
Germantown, MD, USA). Following purification, 1000 ng were reverse transcribed with the High
Capacity cDNA Reverse Transcription Kit (ThermoFisher, Waltham, MA, USA). The cDNA was diluted
to 5 ng/µL and 105 µL was mixed with an equal volume of 2X TaqMan® Fast Advanced Master
Mix. For real-time PCR, 100 µL of the mix was applied to each of two channels on a TaqMan Low
Density Hepatotoxicity Array (TLDA) (Supporting Information Table S1) (ThermoFisher, Waltham,
MA, USA). Four biological samples were loaded on each array with five samples per each group
analyzed. Analysis was performed using the ExpressionSuite Software v1.1 (ThermoFisher, Waltham,
MA, USA).
2.8. Analysis of the Gut Microbiome
Fecal samples from individual mice were placed into collection tubes containing a nucleic
acid stabilizer (Zymo Research, Irvine, CA, USA). Bacterial DNA extraction was performed using
ZymoBIOMICS DNA Kits (Zymo Research). In total, 400 ng of each sample was used for tagmentation
and library preparation, as directed by manufacturer’s protocol of KAPA HyperPlus Kit (Roche,
Madison, WI, USA). Then, each library was purified using AMPure XP bead (Beckman Coulter,
Indianapolis, IN, USA). Normalized libraries were pooled and pair-end sequencing using the Illumina
NextSeq 500 platform to obtain 150 bp paired-end reads was performed.
Raw Illumina fastq files were preprocessed to ensure that only the high-quality reads would be
used for further bioinformatics analysis; adapter trimming and quality filtering were performed using
Trimmomatic software version 0.36 with default parameters [46]. High quality fastqs were further used
as the inputs for reference taxonomic classification and quantification using Centrigue version 1.0.4
with default parameters to generate species profile [47]. Profiles were then visualized on a taxonomic
hierarchy using Pavian package for comparison purposes. The high quality reads were used for
de novo assembly binning to construct high quality metagenomic gene profiling using the metaWRAP
pipeline—a flexible pipeline for genome-resolved metagenomic data analysis with default parameters
except using the mouse genome (mm10) to account for host contamination. Non-redundance gene
sets were constructed as per Foong et al. from the obtained ORFs of the samples using Usearch fast
clustering with identity cutoff of 95% and overlap length of 90% [48]. The constructed non-redundance
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gene sets were then translated into amino acid sequences for KEGG pathway annotation using
ghostKOALA pipeline [48,49]. Differential abundance analysis of taxonomic and gene profiles were
performed from the count data using DESeq2 package [50]. The adjusted p-values were then used for
KEGG pathway enrichment analysis using piano package [51]. Pathways that had enrichment p-value
of < 0.001 were selected to plot heatmaps. Raw sequence reads have been uploaded to NCBI, accession
ID: PRJNA523806.
2.9. Statistical Analysis
All statistical analyses were performed with the GraphPad Prism 6 software (GraphPad Software.
San Diego, CA, USA). Treatment groups were compared with their respective untreated group using
ANOVA followed by Tukey’s multiple comparison test. In cases where the data was not normally
distributed, a Kruskal-Wallis test followed by a Dunn’s multiple comparisons test was used instead.
3. Results
3.1. Phytochemical Characterization of Dgte Utilized in the Study
Phytochemical characterization of utilized dGTE is presented in Table 1. The catechin composition
of the characterized product was comparable to the catechin composition in the product used in other
animal studies with no more than 10% difference for each particular catechin ingredient.












Sum of catechins 255.3
Sum of E-catechins 243.0
3.2. Studies on Acute dGTE Toxicity
Acute toxicity was investigated 24 h after a single gavage of mice with either 1X, 3X or 10X MED of
dGTE to determine if dGTE can cause hepatotoxicity in a fed state. Significant decreases in body weight
were observed in mice gavaged with 10X MED (12%, p < 0.001) (Figure 1A). The liver-to-body weight
ratio was slightly but significantly decreased in all experimental groups (Figure 1B). Moderate changes
in the organ-to-body weight ratios were also observed in the heart but not in the kidney (Supporting
Information Figure S1A,B). No appreciable differences in cytoplasmic vacuolation, apoptotic or mitotic
events, nor steatosis were observed in the livers of control versus experimental animals (Figure 1C).
Analysis of clinical biochemistry did not reveal any substantial changes in any of the evaluated
parameters, besides the insignificant nearly two-fold increase in ALT and ~20% increase in AST after
gavage with 1X MED (Table 2). To determine if dGTE had any effect on glutathione concentration or
generation of reactive oxygen species (ROS) in the liver, we measured both total (GSH+GSSG) and
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oxidized (GSSG) glutathione. dGTE dose-dependently decreased hepatic GSH+GSSG content at 24 h,
with ~40% (p < 0.05) depletion at 10X MED (Figure 1D). On the molecular level, only two genes out of
84 investigated were significantly deregulated—Lss and Chrebp. The expression of both genes was
decreased; however, the extent of the changes was low (below 2-fold) (Figure 1E).
















24 h  Units  Vehicle  1X  3X  10X 
Total Bilirubin    mg/dL  <0.2  <0.2  <0.2  <0.2 
ALT  U/L  28.8 (±8.8)  52.6 (±20.2)  34.4 (±14.8)  32.2 (±11.9) 
AST    U/L    66.2 (±5.7)  84.2 (±8.2)  65.2 (±9.8)  68.2 (±10.3) 
GGT    U/L  <3.0  <3.0  <3.0  <3.0 
Alkaline Phosphatase    IU/L    197 (±3.8)  196.2 (±7.3)  163.8 (±13.5) *  189.8 (±6.4) 
2 weeks  Units  Vehicle  1X  3X  10X 
Total Bilirubin    mg/dL  <0.2  <0.2  0.2  <0.2 
ALT  U/L    28.8 (±8.8)  24.8 (±2.3)  34.2 (±14.4)  33.5 (±11.6) 
AST    U/L    66.2 (±5.7)  49.2 (±12.9)  70.8 (±13.9)  67.6 (±10.4) 
GGT    U/L    <3.0  4.8 (±1.3)  <3.0  <3.0 
Alkaline Phosphatase    IU/L    148 (±4.5)  91.6 (±12.9) **  131.2 (±18.1)  140.2 (±6.7) 
Data presented as mean +/‐ SEM (n = 5 per group) * p < 0.05, ** p < 0.01 compared to vehicle. 
i . alysis f t t i it . Body eights ( ) a li er-t -body eight r ti ( ).
i i li i l i i l
. l t t i e ( ). RNA levels of L s and Chrebp genes (E). * p < 0.05, ** p < 0.01,
*** p < 0.001; mean +/- SEM (n = 5 per group).
Table 2. Clinical chemistry parameters after dosing with dGTE for 24 h and 2 weeks.
24 h Units Vehicle 1X 3X 10X
Total Bilirubin mg/dL <0.2 <0.2 <0.2 <0.2
ALT U/L 28.8 (±8.8) 52.6 (±20.2) 34.4 (±14.8) 32.2 (±11.9)
AST U/L 66.2 (±5.7) 84.2 (±8.2) 65.2 (±9.8) 68.2 (±10.3)
GGT U/L <3.0 <3.0 <3.0 <3.0
Alkaline Phosphatase IU/L 197 (±3.8) 196.2 (±7.3) 163.8 (±13.5) * 189.8 (±6.4)
2 weeks Units Vehicle 1X 3X 10X
Total Bilirubin mg/dL <0.2 <0.2 0.2 <0.2
ALT U/L 28.8 (±8.8) 24.8 (±2.3) 34.2 (±14.4) 33.5 (±11.6)
AST U/L 66.2 (±5.7) 49.2 (±12.9) 70.8 (±13.9) 67.6 (±10.4)
GGT U/L <3.0 4.8 (±1.3) <3.0 <3.0
Alkaline Phosphatase IU/L 148 (±4.5) 91.6 (±12.9) ** 131.2 (±18.1) 140.2 (±6.7)
Data presented as mean +/- SEM (n = 5 per group) * p < 0.05, ** p < 0.01 compared to vehicle.
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3.3. Studies on Sub-Acute dGTE Toxicity
Sub-acute toxicity was investigated after 2 weeks (Mon-Fri) of daily gavage with either 1X, 3X or
10X MED dGTE. A statistically significant decrease in body weight (8%, p = 0.012) was observed after
gavaging mice with 1X MED dGTE compared to control mice at the end of the study (Figure 2A). No
differences in body weight were observed after 3X and 10X MED dGTE. Gavaging with dGTE did
not cause any changes in liver-to-body weight ratio (Figure 2B) as well as heart-to-body weight ratios
(Supporting Information Figure S2A). A small increase in kidney-to-body weight ratio was observed in
mice gavaged with 1X MED dGTE (Supporting Information Figure S2B).
Similar to the acute toxicity study, there were no histomorphological changes in the livers of
experimental animals (Figure 2C). Furthermore, no changes were observed in the evaluated serum
parameters except for the ~30% decrease in ALP in mice gavaged with 1X MED dGTE (Table 2).
GSH+GSSG did not differ between groups after 2 weeks (Figure 2D), indicating compensatory GSH
synthesis with prolonged exposure. Although the ratio of GSSG to GSH was significantly increased
after GTE treatment at 24 h (data not shown), the absolute amount of GSSG was unchanged at both
24 h and 2 weeks (Figure 2E).
Gene expression analysis revealed only one (1) out of 84 genes significantly deregulated, Mcm10,
increased expression of which was observed after administration of 10X MED dGTE (1.9-fold, p < 0.01)
(Figure 2F).






















*significantly  different  from  Day  1  within  a  dose  group)  and  liver‐to‐body  weight  ratio  (B). 




i r . Analysis of dGTE sub-acute toxicity. Body weights ((A) # significant compared to
vehicle, *significantly different from Day 1 within a dose group) and liver-to-body weight ratio
(B). Photomicrograph of intact liver after gava ing mouse with 10X MED dGTE for 2 eeks ( ).
, t t l l t t i ( ) a levels of cm10 gene (F). . , . ;
p < 0.05 compared to vehicle (F); mean +/- SEM (n = 5 per group).
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3.4. Studies on the Gut Microbiome
Next, we sought to investigate whether or not orally administered dGTE affected the gut
microbiome of lean mice. We selected 3X MED (equivalent of ~200 mg/kg/bw) since this is a dGTE
dose analogous to that commonly consumed by humans [52].
We report that gavaging lean B6C3F1 mice with 3X MED dGTE for the period of two weeks,
caused substantial perturbations in the mouse gut ecology. Taxonomic profiling using Centrifuge
software identified a clear discrimination between the control and dGTE mice (Figure 3A). At the
cut-off of 0.5% relative abundance, B. thetaiotaomicron, a common resident bacteria in a mouse gut,
was the most abundant species, followed by L. johnsonii, Akkermansia muciniphila, Lachnoclostridium
sp. YL32, Parabacteroides sp. YL27 and Ruminoclostridium sp KB18 (Figure 3B). Administration of dGTE
caused an increase in the Bacteroidetes to Firmicutes ratio (Figure 3C,D). Interestingly, only A. muciniphila
abundance was dramatically increased in the dGTE group compared to control in the high abundance
taxa (Figure 3C,D) with the most statistically significant adjusted p-value of 1.75e-7 (Supporting
Information Figure S3, Table S2). Based on KEGG pathway analysis, increased abundance of genes
associated with glycan degradation-related pathway in dGTE group compared to control was found
(Figure 3E). As mucin is composed of different types of glycans, this correlates with the increased
abundance of A. muciniphila, which is the main consumer of mucin in both human and animal gut [53].
On the other hand, decreased abundance of genes related with Salmonella infection, bacterial chemotaxis
and bacterial mobility proteins in dGTE group was noted.
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4. Discussion
To assess the hepatotoxic potential of dGTE, we utilized an integrative approach similar to
our other recent studies for the safety assessment of multi-ingredient botanical dietary supplement
formulations [54,55]. This approach considers analyses based upon: (1) the number of end-points
characteristic for liver injury; (2) a dose range of 1X to 10X MED (65.9 to 659 mg/kg bw/day of
dGTE for this study); and (3) single and repeated dosing studies. This allows for a fast and
comprehensive investigation of phytochemical hepatotoxicity as well as provide insight into potential
toxicological mechanisms.
Our findings are in agreement with previous pre-clinical and clinical studies on dGTE
hepatotoxicity that reported a lack of liver injury at doses below ~750 mg/kg bw/day [13,16,52].
Despite administering dGTE at doses as high as 10X MED, no appreciable toxicological responses were
observed in experimental mice. Specifically, gavaging mice with dGTE produced no histopathological
abnormalities in the livers and no significant alterations were observed in clinical biochemistry
parameters indicative of liver injury. Small decreases in total glutathione were observed in mice livers
24 h after a single administration of dGTE; however, these effects were short-lived and had disappeared
by day 14. The fact that dGTE had no effect on GSSG at 1X and 3X MED argues against the idea that
orally administered dGTE is an antioxidant and the observed depletion of GSH+GSSG after a bolus
dose of dGTE may even increase the risk of oxidative stress. This finding underscores the necessity of
validating in vitro data using in vivo models and warrants further in vivo studies to investigate the
potential anti- and pro-oxidant effects of GTE [56,57].
Only very modest, dose-independent changes in gene expression were detected in the livers
of dGTE-gavaged mice. Analysis of expression panels for genes involved in xenobiotic metabolism
or hepatocellular responses to toxicants revealed only a small subset (<5%) that was significantly
dysregulated. Importantly, the magnitude of responses in those genes was minimal, with only one
gene, Mcm10, exceeding a 1.5-fold increase from control. Furthermore, reduced expression of Lss
and Chrebp genes that are associated with cholesterol and glycogen metabolism in mice may suggest
potentially beneficial health effects and warrant future studies. No dGTE-induced weight-loss was
observed; however, this can be explained by the lean nature of the mice and the study’s short duration.
It must be noted that our study was performed under conditions that purposefully omitted
other potential contributors to liver injury, such as genetics, fasting and caffeine [16,19,58]. GTE-
or EGCG-induced liver injury is considered idiosyncratic by nature. While the mechanisms of this
idiosyncrasy remain unknown, genetic components seem to play a significant, if not key, role [10,59].
Furthermore, in their elegant study using diversity outbred (DO) mice, Church and colleagues
demonstrated that variations in select genomic loci may predispose to higher sensitivity to EGCG [19].
Therefore, our observed lack of dGTE-induced hepatotoxicity among inbred B6C3F1 mice, a strain
characterized by average sensitivity to hepatotoxicants, is not surprising.
Previous research hints at a contribution of fasting in GTE/catechins-induced liver injury.
For instance, in two classical studies with beagle dogs, fasted animals exhibited high sensitivity
to orally administered EGCG, including mortality at doses of 400 mg/kg bw with No-Observed-
Adverse-Effect-Level (NOAEL) observed at 40 mg EGCG/kg bw/day [16]. At the same time, the
NOAEL in dogs that received food ad libitum was 460 mg/kg bw/day and could potentially have been
higher, as this dose of EGCG was the highest used in the study [16]. In our study, the mice received
food ad libitum, with a NOAEL of 659 mg/kg bw/day.
Furthermore, our study utilized dGTE, thereby precluding any contributory effects from
caffeine [58]. Importantly, in many GTE-associated cases of hepatotoxicity, GTE was one but not
the only, constituent of the formulation. For example, GTE was present in both Hydroxycut™ and
X-elles™, two dietary supplement formulations linked to multiple cases of hepatotoxicity that were
voluntarily withdrawn from the market [14]. Besides GTE, both of those formulations contained
caffeine and a host of other botanical ingredients. Caffeine’s propensity to exacerbate the toxicity of
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other phytochemicals was recently recognized by the FDA, which banned the sale of pure caffeine
powder and dietary supplements containing high caffeine content [60].
Finally, product adulteration with prescription medications (e.g., acetaminophen, amphetamines,
etc.) or contamination with heavy metals, pesticides/herbicides or bacteria cannot be ruled
as contributors to the hepatotoxicity of multi-ingredient, GTE-containing supplements [10,11].
Phytochemical characterization of the dGTE used in the present study revealed no evidence of
adulteration, heavy metal or bacterial contamination.
Accumulating evidence indicates that catechin oral bioavailability is relatively low [13,15–18,34,35].
Our findings, together with a wealth of previously published data, suggest that any dGTE-derived
health effects from catechins, likely stem from dGTE-mediated alterations in the distal gut microbiome
and potential active metabolites generated therein, rather than from catechin absorption in the proximal
intestine. Indeed, even minimal dietary interventions can substantially affect the gut microbiome and
metabolome [61].
It has been proposed that GTE’s health benefits may be linked to the effects catechins exert on
particular bacterial species in the gut. For instance, catechins have been shown to affect the growth
of Bacteroidetes and Firmicutes [62]. It is especially important to note that the relative proportion of
Bacteroidetes to Firmicutes and bacterial alpha diversity are markedly decreased in both obese humans
and obese mice [25,63–65]. Further studies have confirmed EGCG-induced changes to gut ecology [66].
Additionally, administration of green tea polyphenols appears to modulate gut microbiota diversity,
including restoration of the Bacteroidetes to Firmicutes ratio resulting in body weight loss in mice fed
a high fat diet [65]. Interestingly, another recent study that used liquid green tea reported opposite
results with a decrease observed in the Bacteroidetes to Firmicutes ratio [42]. In our study, coincident
with an increased Bacteroides to Firmicutes ratio, we also found an increase in A. muciniphila, a mucin
degrading bacteria, which has been reported as a beneficial gut microbe associated with body fat
reduction, correction of dyslipidemia and reduced insulin resistance [67].
In conclusion, we demonstrate that dGTE, when administered to non-fasting and genetically
uncompromised mice, does not elicit hepatotoxic effects even when administered at doses as high
as 659 mg/kg bw/day. Additional studies, however, will be needed to delineate the role of other
confounding factors like caffeine, which may decrease tolerance to GTE. We further demonstrate that
dGTE doses ~200 mg/kg bw can substantially modulate the gut microbiome, leading to increases in the
health-beneficial bacteria Akkermansia sp. These findings may give insight into the potential weight
management properties of GTE; however, future studies are needed to fully delineate this effect.
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